Met-enkephalin and related proenkephalin A-derived peptides circulate in plasma at picomolar concentration as free, native pentapeptide and at nanomolar concentration in cryptic forms. We have optimized conditions for measurement of immunoreactive Metenkephalin in plasma and for generation by trypsin and carboxypeptidase B of much greater amounts of total peptidase-derivable Met-enkephalin in plasma of rats, dogs, and humans. Free Met-enkephalin (11 pM) is constituted by native pentapeptide and its sulfoxide. Characterization of plasma total Met-enkephalin derived by peptidic hydrolysis revealed a small amount (38 pM) of Met-enkephalin associated with peptides of molecular mass less than 30,000 D, and probably derived from proenkephalin A, but much larger amounts of Met-enkephalin associated with albumin (1.2 nM) and with a globulin-sized protein (2.8 nM). Thus, plasma protein precursors for peptidase-derivable Met-enkephalin differ structurally and chemically from proenkephalin A. Met-enkephalin generated from plasma by peptidic hydrolysis showed naloxone-reversible bioactivity comparable to synthetic Met-enkephalin. Prolonged exposure of adult, male rats to restraint stress produced biphasic plasma responses, with peaks occurring at 30 s and 30 min in both free native and total peptidasederivable Met-enkephalin. Repeated daily exposure to this 30-min stress resulted in adaptive loss of responses of both forms to acute restraint. Initial plasma responses of Metenkephalin paralleled those of epinephrine and norepinephrine, but subsequently showed divergence of response. In conclusion, Met-enkephalin circulates in several […] Abstract Met-enkephalin and related proenkephalin A-derived peptides circulate in plasma at picomolar concentration as free, native pentapeptide and at nanomolar concentration in cryptic forms. We have optimized conditions for measurement of immunoreactive Met-enkephalin in plasma and for generation by trypsin and carboxypeptidase B of much greater amounts of total peptidase-derivable Met-enkephalin in plasma of rats, dogs, and humans. Free Met-enkephalin (11 pM) is constituted by native pentapeptide and its sulfoxide. Characterization of plasma total Met-enkephalin derived by peptidic hydrolysis revealed a small amount (38 pM) of Met-enkephalin associated with peptides of molecular mass < 30,000 D, and probably derived from proenkephalin A, but much larger amounts of Met-enkephalin associated with albumin (1.2 nM) and with a globulin-sized protein (2.8 nM). Thus, plasma protein precursors for peptidase-derivable Met-enkephalin differ structurally and chemically from proenkephalin A. Met-enkephalin generated from plasma by peptidic hydrolysis showed naloxone-reversible bioactivity comparable to synthetic Met-enkephalin.
Introduction
Met-Enkephalin and a number of proenkephalin A-derived peptides are widely distributed within the central nervous system and in many peripheral tissues including adrenal medulla, sympathetic nerve terminals and ganglia, pancreas, gastrointestinal tract, and pituitary (1, 2) . Co-secretion of enkephalinrelated peptides and catecholamines has been demonstrated from chromaffin cells in vitro, from isolated perfused adrenal glands and from adrenal gland in vivo (3) (4) (5) (6) (7) . Although circulating Met-enkephalin has been quantitated by a number of laboratories, considerable variability in plasma concentration has been described (8) . Met-enkephalin is degraded rapidly in plasma and changes in circulating levels in response to stimuli have been difficult to document. Indeed, very little is known regarding the in vivo regulation of secretion of Met-enkephalin-related peptides and of the plasma levels of Met-enkephalin. It has been shown clearly that in a number of tissues, including adrenal medulla and brain, enkephalin-containing peptides are converted to Met-enkephalin in a series of enzymic steps which involve processing by trypsinlike and carboxypeptidase B-like enzymes (9-1 1). The Met-enkephalin in such peptides derived from proenkephalin A has been referred to as cryptic Met-enkephalin. It remains unclear whether Metenkephalin is secreted into the circulation only as a pentapeptide or whether it may be secreted also in a larger protected form, and later hydrolyzed to the pentapeptide. In addition and analogous to other hormones, it seems probable that Metenkephalin also circulates in a bound form, in association with albumin or a globulin.
The physiological relevance of circulating Met-enkephalin remains poorly understood. Inferences have been made from studies employing the opioid antagonist, naloxone. However, conclusions regarding effects of circulating Met-enkephalin, which can be drawn from such studies, have been necessarily limited since naloxone acts at receptors in both periphery and brain and since other circulating endogenous opioids such as fl-endorphin might mediate such naloxone-antagonizable ef- fects. Clearly, in order to better document the physiology of Met-enkephalin acting as a hormone, studies of its circulating forms and their regulation are essential. Thus, during the past few years we have determined to measure immunoreactive Met-enkephalin in plasma, to define more optimal enzymic conditions for the generation of peptidase-derivable Met-enkephalin in plasma, to characterize the large circulating forms of peptidase-derivable Met-enkephalin, and to define iin rats the physiologic regulation ofplasma responses to a psychological stress of free native Met-enkephalin and total peptidasederivable Met-enkephalin. Methods
Materials. Met-O-enkephalin sulfoxide, L-l-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)'-treated trypsin, carboxypeptidase B, BAM-12P, peptide E, and peptide F were obtained from Peninsula Laboratories, Inc., Belmont, CA. Porapak Q (80-120 mesh) was obtained from Waters Associates-Millipore, Milford, MA; aprotinin (Trasylol) from Mobay, New York, and polyethyleneglycol (PEG), molecular mass 8,000 D, from Aldrich Chemical Co., Milwaukee, WI. Commercial antiserum, anti-Met-enkephalin 18R2, was obtained from Immunonuclear Corp., Stillwater, MN, and '25I-Met-enkephalin was obtained from New England Nuclear-Dupont, Wilmington, DE. Disodium EDTA, citric acid, sodium phosphate monobasic and dibasic, and magnesium sulfate were obtained from Fisher Scientific Co., Fair Lawn, NJ; Spectrapor membrane tubing from Spectrum Medical Industries, Los Angeles, CA; Affi-Gel Blue (50-100 mesh wet) from Bio-Rad Laboratories, Richmond, CA; and Diaflo Ultrafilters PM30 and Centricon-100 from Amicon Corp., Danvers, MA. Eqithesin was made from 2.13 g of chloral hydrate, 1.04 g magnesium sulfate, 14.1 ml of propylene glycol, 9.75 ml of Nembutal, 3.78 ml of ethanol, and adjusted to 50 ml in volume with 22.4 ml of water.
Collection ofblood. Blood for Met-enkephalin estimation was collected on ice in polypropylene tubes in EDTA 2.7 nmol/ml of blood, citric acid 17.7 umol/ml of blood, and aprotinin 200 kIU/ml blood (12) . Blood was centrifuged at 40,000 g for 30 min at 4°C, then plasma was acidified with 0.5 N HC1 final concentration, and stored at -70°C until assay. Blood for norepinephrine and epinephrine to be measured by a single-isotope radioenzymatic assay (13) was collected into chilled polypropylene tubes containing 2 mg of DTT and 10 Ml of 10% EGTA. Blood was centrifuged at 30,000 g for 10 min and the deproteinized plasma was stored at -70°C until assay.
Extraction of native Met-enkephalin from plasma. Acidified plasma, 300 Al, was neutralized with 2 ml of 0.06 M phosphate buffer, pH 10.2; this phosphate buffer was prepared from sodium phosphate monobasic 0.07 M and sodium phosphate dibasic 0.05 M, then pH adjusted with sodium hydroxide 10 N. Samples were applied to Porapak Q columns composed of 250 mg of Porapak Q in 3 ml of absolute ethanol (200 proof). Porapak Q slurry was prepared by degassing overnight 25 g in 350 ml of absolute ethanol. Shortly before applying the samples, columns were equilibrated with 6 ml of doubly distilled water; then loaded columns were washed with 3 ml of doubly distilled water, and Met-enkephalin was eluted with 3 ml of absolute ethanol, lyophilized overnight and assayed immediately. Radioimmunoassay of Met-enkephalin in plasma. Commercial Met-enkephalin antiserum 18R2 raised in rabbit was examined for cross-reactivity with the following peptides: Met-O-enkephalin, Metenkephalin, Tyr-Gly-Gly-Phe, Gly-Gly-Phe-Met, Leu-enkephalin, Met-enkephalin-Arg6-Phe7, Met-enkephalin-Arg6-Gly7-Leu8, metorphamide, peptide B, peptide BAM-12P, peptide E, and peptide F.
Lyophilized samples were reconstituted with 100 Ml of 0.06 M phosphate buffer, pH 6.5, containing 0.2% of bovine serum albumin and 0.002% sodium azide. 50 ,ul of antiserum diluted 1: 10,000 and 50
Ml of I25I-Met-enkephalin (-1,500 cpm) were added and samples were incubated at 4°C. After 24 h of incubation, 50 Ml of 1% rabbit y-globulin were added and incubation was maintained at 4°C for 30 min. Separation of bound from free complex was performed by adding 250 Ml of 25% PEG. After 30 min of incubation, samples were centrifuged at 2000 g at 4°C for 30 min, supernatant was discarded, and pellets were counted in y-counter (Packard Instrument Co., Inc., Downers Grove, IL).
Recovery of Met-enkephalin from Porapak Q was studied by extraction of Met-enkephalin from phosphate buffer or plasma and comparison with unextracted Met-enkephalin standard. Recovery of immunoreactive Met-enkephalin standard from 0.5 N HCl was examined after lyophilization at pH 6.0, reconstitution in buffer and extraction with Porapak Q columns. Recovery of Met-enkephalin was also studied by comparing the recovery of '251-Met-enkephalin (-S Total peptidase-derivable Met-enkephalin in plasma. To release Met-enkephalin from larger molecular forms present in plasma or from Met-enkephalin bound to plasma protein (together with free these comprise total Met-enkephalin), different conditions for enzymic hydrolysis were compared. Plasma was incubated for 30 min at 370C with TPCK-treated trypsin in concentrations of 300-2,000 ,ug/ml. Immediately after, plasma was incubated for 15 min with carboxypeptidase B, 10-100 Ag/ml plus trypsin inhibitor 2.5 mg/ml. From different combinations of trypsin and carboxypeptidase B described above, the optimal conditions were determined (Table I) . In subsequent studies for preparation of total plasma Met-enkephalin, 50 The maximum blood volume withdrawn at any time point was 0.8 ml and the maximum blood volume withdrawn from one rat in any experiment was 3.5 ml. The effect of frequent blood sampling on the levels of Met-enkephalin was examined using several protocols in these experiments. In two experiments, 260 Ml of blood was withdrawn from control and stressed rats at 1 min before stress and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 7, and 10 min after the onset of stress. In other experiments, 0.5 ml was withdrawn at 1 min before stress and at 2, 10, 20, and 30 min after the onset of stress, or 0.8 ml was withdrawn at 1 min before stress and at 1, 15, and 30 min after the onset of stress.
In order to determine whether repeated application of stress alters the plasma Met-enkephalin responses to stress, rats were stressed 30 min daily for 
Results
Characterization ofRIAfor Met-enkephalin in plasma. Recovery of Met-enkephalin standard over range of 0.4-200 pg in the RIA including extraction from Porapak Q was 80% from buffer and 95% from 1 ml of acidified plasma (after subtraction of the endogenous Met-enkephalin in this plasma). When standard Met-enkephalin was prepared in 0.5 N HCO (to mimic acidification conditions for handling the plasma), then brought to pH 6 with buffer, extracted on Porapak Q, and assayed, recovery was 75%. Recovery of '25I-Met-enkephalin (20 ,000 cpm, -5 pg) from Porapak Q was 80.0±3.1%; these data suggest that recovery of Met-enkephalin is absolute from aspects of the assay procedure other than extraction on Porapak Q (Fig. 1) . Intra-and interassay coefficients of variation are 7% and 1 1%, respectively.
Cross-reactivity of a number of related peptides with antiserum to Met-enkephalin was studied (Fig. 2 ). Using 1 pmol of peptide, cross-reactivities were: Met-O-enkephalin sulfoxide, 160%; peptide F, 22%; peptide E, 2%; Leu-enkephalin, 1.8%; peptide B, 0.8%; Met-enkephalin-Arg6-Phe7, 0.6%; Met-enkephalin-Arg6-Gly7-Leu8, 0.1%; metorphamide, 0.09%; peptide BAM 12P, 0.07%; Tyr-Gly-Gly-Phe and Gly-Gly-PheMet, < 0.01%. Thus, only Met-enkephalin sulfoxide and peptide F showed significant cross-reactivity with this Met-enkephalin antiserum.
Parallelism of native endogenous Met-enkephalin in plasma of rat, human, and dog with Met-enkephalin standard is demonstrated in Fig. 3 .
Characterization ofplasma native immunoreactive Met-enkephalin. Reverse-phase HPLC of standard Met-enkephalin consistently reveals two peaks of immunoreactive Met-enkephalin in both systems. The first peak coelutes with Met-enkephalin sulfoxide and the second peak with Met-enkephalin. The relative proportion ofthese two peaks to each other varied considerably from one study to another; it appears that Metenkephalin is variably converted to its sulfoxide during storage, lyophilization, Porapak Q extraction, and HPLC. HPLC of rat plasma also consistently reveals two peaks ofimmunoreactive Met-enkephalin, the first peak also coeluting with Metenkephalin sulfoxide and the second peak with Met-enkephalin. Fig. 4 presents an example of HPLC of rat plasma spiked with standard Met-enkephalin which had been extracted and chromatographed in duplicate. In this particular example, a third small peak intermediate between the other two was noted in each of the duplicate plasma samples; however, this small peak was not a consistent finding in other experiments.
Characterization ofpeptidase-derivable Met-enkephalin in plasma. Peptidase-derivable Met-enkephalin refers to cryptic Met-enkephalin present in larger peptides or proteins, or asso-9'r- ciated with protein, and which can be generated by enzymic hydrolysis With trypsin and carboxypeptidase B. Treatment of plasma consecutively with trypsin and carboxypeptidase B results in a substantial increase in Met-enkephalin concentration. Using the hydrolytic conditions described previously (4, 17), we found an increase in plasma Met-enkephalin from 7.1±0.4 (native) to 26.1±2.1 pM (total). However, when we optimized these hydrolytic conditions, we obtained a much larger concentration of total Met-enkephalin (Table I) . Currently, for generation of total Met-enkephalin in plasma we use incubation for 30 min with trypsin 1,000 Ag/ml followed by incubation for 15 min with carboxypeptidase B 50 Ag/ml plus trypsin inhibitor 2,500 #gWml. Addition of cobalt chloride 0.1-50 mM to the incubation with carboxypeptidase B did not enhance the generation of Met-enkephalin. We have found subsequently that addition of cobalt chloride 1 mM to the incubation with trypsin does enhance the generation of Metenkephalin. Identical concentrations of peptidase-derivable Met-enkephalin were obtained using plasma volumes over a range of 0.01-0.5 ml. Parallelism of total endogenous peptidase-derivable Met-enkephalin in plasma ofrats, humans, and dogs with Met-enkephalin standard is demonstrated in Fig. 5 alin. We examined the effectiveness of our hydrolytic conditions to cleave a number of known proenkephalin A-derived peptides (Table II) . The smaller peptides, Met-enkephalinArg6-Phe7, Met-enkephalin-Arg6-Gly7-Leu8 and metorphamide, were cleaved to Met-enkephalin more readily and more completely than the larger peptides, peptides B, E, and F.
Guanidine hydrochloride 6 M, urea 8 M, and mercaptoethanol 1 M, were ineffective in generating from plasma the large amount of immunoreactive Met-enkephalin derived by proteolytic cleavage with trypsin and carboxypeptidase B (Table III) . However, guanidine and mercaptoethanol did generate a small amount of Met-enkephalin from plasma, increasing the native concentration about 2.5-fold and 4-fold, respectively. Guanidine together with mercaptoethanol did not generate more Met-enkephalin than mercaptoethanol alone.
Plasma was filtered through a membrane with cutoff molecular mass < 30,000 D. Hydrolysis of the filtrate containing peptides with molecular mass < 30,000 D provided < 1% of the total Met-enkephalin. Met-enkephalin found after hydrolysis of the washings of the membrane which contained peptides and proteins of > 30,000 D released > 99% of the total Met-enkephalin (Table IV) . We carried out a further experiment in which we filtered plasma through a membrane with cutoff molecular mass < 100,000 D. Pretreatment of plasma with guanidine plus mercaptoethanol failed to increase the amount of either native or peptidase-hydrolyzable Met-enkephalin which was filtered or the amount remaining in the retentate. Affi-Gel Blue chromatography was used to separate albumin from other proteins in the fraction containing peptides and proteins of molecular mass > 30,000 D. Enzymic hydrolysis of the supernatant obtained from centrifugation of the washed and resuspended Affi-Gel Blue pellet and, which contains mainly albumin, provided only 14% of total peptidase-derivable Met-enkephalin. In contrast, hydrolysis of the initial supernatant plus the washings from Affi-Gel Blue chro- (Fig. 6 C) corresponding to the globulin peak of plasma protein (Fig. 6 A) and approximately with our thyroglobulin standard, molecular mass 669,000 D (Fig. 6 B) . A second large Met-enkephalin peak (22% of total) was found in fractions 32-37 corresponding to the albumin standard (67,000 D) and to the albumin peak of plasma protein. A third small peak (1 1%) of Met-enkephalin in fractions 28-31 corresponded to a Met-enkephalin-Arg6-Phe7 12 42 Met-enkephalin-Arg6-Gly7-Leu8 shoulder on the front of the albumin peak of plasma proteins and to protein of molecular mass 100,000-150,000 D. It is unclear whether two other peaks of Met-enkephalin were present on the back shoulder of the larger globulin peak between 250,000 and 500,000 D. These findings of multiple high molecular mass protein peaks which release immunoreactive Met-enkephalin upon peptidic hydrolysis were replicated on Sephadex G-200 chromatography on three separate occasions. Bioactivity ofpeptidase-derivable Met-enkephalin. Plasma extract which had been hydrolyzed with trypsin and carboxypeptidase B to release total Met-enkephalin and extracted on Porapak Q was run on reverse-phase HPLC. Fractions representing Met-enkephalin and Met-enkephalin sulfoxide were studied individually in a mouse vas deferens assay to quantitate bioactive Met-enkephalin. The responses of authentic Met-enkephalin pentapeptide obtained from aliquots representing 11.2 and 22.4 ml of plasma are compared with the responses to Met-enkephalin standard in Fig. 7 . These data provided an estimate for plasma concentration of bioactive peptidase-derivable Met-enkephalin of 3,973 pM; very comparable to our estimates of plasma concentration of immunoreactive Met-enkephalin. Met-enkephalin sulfoxide isolated by HPLC from the enzymically hydrolyzed plasma pool appeared to be at least as potent in this bioassay system as the similarly isolated Met-enkephalin. Furthermore, the effects of both plasma peptidase-derivable Met-enkephalin and its sulfoxide to inhibit electrically-induced contraction of mouse vas deferens were reversed completely by addition of naloxone to the perfusion bath at a time when the peptides were maximally active.
Plasma Met-enkephalin responses to restraint stress. Time courses of plasma native and peptidase-derivable Met-enkephalin responses to restraint stress are shown in Fig. 8 Nonstressed control animals did not show any significant changes in plasma level of native Met-enkephalin during the entire period of the experiments. Since withdrawal of large volumes of blood may result in sympathoadrenal activation, it was necessary to demonstrate that our blood sampling protocols did not increase plasma Met-enkephalin concentration. The effect of repeated blood sampling on plasma Met-enkephalin levels was examined using several protocols in these experiments. Neither frequent withdrawals of a small volume (0.26 ml) for a total withdrawal of 2.6 ml ofblood over 10 min in 300-g rats nor less frequent withdrawals of larger volumes (0.5-0.8 ml) for a total withdrawal of 3.5 ml of blood over 30 min resulted in elevation of plasma native Met-enkephalin.
Similar to native Met-enkephalin, plasma peptidase-derivable Met-enkephalin response was maximal at 0.5 min of restraint, increasing from a basal level of 3,450 to a peak of 5,260 pM, but this response was somewhat more prolonged than that for native Met-enkephalin. Plasma peptidase-derivable Metenkephalin returned to basal level by 7 min. Plasma peptidase-derivable Met-enkephalin again showed an elevated level at 30 min ofrestraint stress (from 3,193+49 to 4,289±76 pM), but this response was much less than the initial response at 0.5 min of stress. Plasma peptidase-derivable Met-enkephalin levels in control unstressed animals did not show any statistically significant differences during the experiment. Also similar to native Met-enkephalin, our blood sampling protocols did not produce changes in plasma concentration of total Met-enkephalin.
Time courses of plasma norepinephrine and epinephrine responses to restraint stress are shown in Fig. 9 ; each value is the mean ofone to eight different experiments. Plasma norepinephrine increased from a basal level of 1.45+0.15 to a peak of 5.19±0.39 nM, also at 0.5 min of restraint. The peak plasma level of norepinephrine lasted for the next 0.5 min of stress (P < 0.01), then declined slowly but still remained significantly (P < 0.05) elevated to the end of the 30 min of restraint. Plasma epinephrine increased from a basal level of 1.68±0.24 to a peak of 12.69±0.64 nM, also at 0.5 min of restraint, then decreased to 6.42±0.81 nM by 2 min and declined slowly to 4.9± 1.0 nM by 30 min of stress; this concentration was still elevated above basal level (P < 0.01). Control animals did not show any significant changes in the plasma concentrations of norepinephrine and epinephrine during experiments.
Since it has been demonstrated that repeated administration of an identical stressor resulted in adaptation of catecholamine responses (18) , it was of interest to study possible significantly elevated above baseline at the end of the 30-min stress. In contrast to epinephrine, on day 7 plasma norepinephrine did increase significantly above the basal concentration but did not remain elevated throughout the 30-min period of stress.
Discussion
We have described a very sensitive method for measurement in plasma (and other biological fluids) of native and peptidase-derivable Met-enkephalin. This method employs a commercial antiserum and a tracer radiolabeled either commercially or in our laboratory. Radioimmunoassays for Met-enkephalin described previously have reported a wide range for basal plasma concentration (8) . This variation may relate to differences in methods of blood collection, in methods of extraction of peptide from plasma, and in antisera. Previously, we had found that published methods of blood collection for Met-enkephalin were not optimal, and we introduced the use of citrate to prevent degradation of the pentapeptide (12) . We found citrate to be more effective in this regard than the specific aminopeptidase inhibitor, bestatin, and subsequently we reduced the final concentration of citrate from 23 to 17 mM to prevent hemolysis which occurs with citrate in some blood, particularly sheep blood. We also use aprotinin to prevent degradation of large precursor peptides to Met-enkephalin. In unpublished studies, we found that addition of EDTA did not affect the final concentration of Met-en- . Plasma epinephrine and norepin tial (day 1,*) and repeated daily (day 7, o) (i±SEM). *Significant difference at P < 0.0 tion at time -1 min. Significant difference centration at corresponding day 7 time poir the overall curve from baseline at P < 0.01.
kephalin detected. Also, heparin did i tivity of native Met-enkephalin. Howe with EDTA or heparin in addition ti resulted in lower concentrations of i dase-derivable Met-enkephalin than sence. Acidification of plasma is an ih taining the stability of Met-enkephalin Porapak Q, a porous copolymer of benzene cross-linked with divinylben to be effective in absorbing enkephal Porapak Q very effective in extractin plasma of the human, rat, dog, and si and others (20) have found C18 resin r octadecylthrichlorosilane provides po kephalin from plasma (21) . Acid-acetl used effectively when large volumes i concentrations of Met-enkephalin are Several assays for Met-enkephalin generated against Met-O-enkephalin cross-react with Met-enkephalin but re ples before assay. In our assay, Metwas even more immunoreactive thai only other peptide which showed c (-20%) was Peptide F. Kraemer et E levels of peptide F to be considerab] Met-enkephalin in human plasma. Sii plasma has not been reported.
Incubation of adrenal cell culture n with the peptidases, trypsin and carbx Met-enkephalin from proenkephalin / INE peptidic intermediates. Peptidic hydrolysis of large peptides and proteins in plasma may yield a number of biologically CONTROL active peptides (8, 10, 22, 25, 26) . Thus, extracellular and even intravascular production of peptides by limited proteolytic cleavage from secreted precursors may represent a physiologic mechanism of origin of bioactive peptides. Proteases such as trypsin may act in a manner similar to an enzyme such as kallikrein which physiologically processes kininogen to bradykinin-related peptides (27, 28) . Potential cleavage sites and proteolytic mechanisms have been reviewed elsewhere (10, 25, 27, 28). As we noted above, incubation of plasma with concentrations of trypsin and carboxypeptidase B used in those published studies increased the yield of immunoreactive Metenkephalin by about threefold. When we increased the concentration of these peptidases to a more optimal level, we RINE increased the yield of Met-enkephalin from plasma greatly to 350-fold. Furthermore, we have found that acid hydrolysis using lyophilization of plasma in strong acid also yields large amounts of immunoreactive Met-enkephalin in plasma (29) . In contrast to the report of Singer et al. (22) (Table II) . mportant step in mainNeither arylsulfatase nor fl-glucuronidase generated Meti in plasma.
enkephalin from plasma (29) , suggesting that Met-enkephalin styrene and ethylvinyldoes not circulate in significant concentration as a conjugate of zene, has been reported either sulfate or glucuronide. Incubation of plasma with guains (12, 19) . We found nidine hydrochloride generated a small amount of Met-eng Met-enkephalin from kephalin, suggesting that this small amount of Met-enkephalin heep. We (unpublished) might circulate in noncovalent association with albumin. Also, nuch less effective; also, generation of a small amount of native Met-enkephalin by for recovery of Met-enincubation of plasma with mercaptoethanol suggests that some one extraction has been Met-enkephalin is linked to protein by disulfide bonds. Howof plasma or very high ever, none of guanidine hydrochloride, urea, or mercaptoethavailable (22) .
anol generated the large amount of Met-enkephalin seen folhave employed antisera lowing enzymic cleavage with trypsin and carboxypeptidase B, sulfoxide which do not suggesting further that this total peptidase-derivable Met-enDquire oxidation of samkephalin in plasma is not present simply in noncovalent or -O-enkephalin sulfoxide disulfide bonding to protein. Also, pretreatment of plasma n Met-enkephalin. The with guanidine plus mercaptoethanol, before their filtration -ross-reactivity of note through a membrane with cutoffof molecular mass < 100,000
al. (23) reported plasma D did not result in an increase in Met-enkephalin which could ly higher than those of be released by peptidic hydrolysis; these data suggest that this milar comparison in rat peptidase-derivable Met-enkephalin is not present simply in proenkephalin A bound noncovalently to larger proteins. Furnedium (4) or tissue (24) thermore, it seems likely that the Met-enkephalin sequence is (33) generated from rat serum albumin a peptide which was immunoreactive in their Met-enkephalin RIA, but which was more hydrophilic and had a different pl from authentic Met-enkephalin. Our data with both Sephadex G-200 chromatography and with Affi-Gel Blue chromatography suggested that 14-22% of the immunoreactive Met-enkephalin which we generated from plasma derived from albumin or a protein of similar molecular weight. Thus, it appears that trypsin (in our hands) or pepsin (in the hands of other investigators [22, 33] but not in our hands) are able to lyse albumin or a closely related protein to yield immunoreactive Met-enkephalin. The major peak of immunoreactive Met-enkephalin which we obtained upon sequential digestion with trypsin and carboxypeptidase B of fractions from Sephadex G-200 chromatography of rat plasma was not albumin, but rather a protein of the size of a globulin with molecular mass > 600,000 D. In any case, and while it is not possible to entirely rule out the possibility that preproenkephalin A is bound to a large protein, it is clear from our studies and from those of others (22, 30, 33) that largely the plasma protein precursors for peptidase-derivable Met-enkephalin and related peptides differ structurally and chemically from proenkephalin A.
Possenti et al. (34) Previous studies have documented the co-secretion of immunoreactive Met-enkephalin and catecholamines from chromaffin cells in culture (3, 4) , from isolated perfused adrenal glands (6, 7) , and from dog adrenals in vivo (5) . However, plasma Met-enkephalin responses to stimuli have been documented in relatively few studies (cf. 8, [37] [38] [39] . In this study, we describe in rats consistent rapid increases in plasma immunoreactive native Met-enkephalin in response to restraint, a psychological stress. Plasma native Met-enkephalin peaked in parallel with the increases in plasma epinephrine and norepinephrine. Thereafter, there was a divergence in the plasma concentrations of Met-enkephalin and catecholamines during the period ofrestraint stress. Plasma Met-enkephalin showed a biphasic response to 30 min of restraint. A somewhat similar phasic response pattern has been reported for plasma epinephrine and norepinephrine in response to hemorrhage, with an initial peak within 5 min and a second peak at 20-30 min (40). Also, the apparently rapid clearance of the large molecular mass proteins which yield the peptidase-derivable Met-enkephalin may relate to increased secretion of large protein for only a very brief period after onset of stress; then, the apparent clearance of the large protein would in fact reflect clearance of Met-enkephalin. Whether these phases of Met-enkephalin response represent secretion from different compartments in the same tissue similar to that seen with insulin (41) or secretion from different tissues remains unknown. It seems probable that the brief duration of the initial peak of plasma Met-enkephalin induced by restraint stress is a result of a central nervous system regulatory mechanism rather than of a limitation in Met-enkephalin pool size, since the more severe stress of immobilization produced a prolonged elevation of plasma Met-enkephalin (42) .
The adrenal medulla has seemed to most investigators to represent the most probable source ofcirculating Met-enkephalin, and we have found that in dogs adrenal secretion rate of native Met-enkephalin increases briskly in response to insulin-induced hypoglycemia (8) or nicotine (43) . On the other hand, the adrenomedullary concentration of Met-enkephalin is considerably lower in rats than in other species (44) . We have carried out a study to determine the sympathetic nerve and adrenomedullary contributions to the plasma Met-enkephalin increases seen in response to restraint in rats (45) . Chemical sympathectomy with guanethidine, but not adrenal demedullation, prevented the plasma native Met-enkephalin response to restraint stress. These data suggest that in rats the restraint stress-induced increase in plasma native Met-enkephalin is derived largely from sympathetic nerves and not from the adrenal medulla. It is well known that plasma catecholamine concentrations in trunk blood after decapitation are markedly higher than those in blood taken from an indwelfing cannula (18) , presumably because of massive adrenomedullary discharge associated with decapitation. In contrast, plasma Met-enkephalin concentration does not appear to be affected by decapitation in rats. This may also argue against the adrenal medulla as a major source of circulating Met-en-.kephalin in rats. We have been unable to reduce basal plasma Met-enkephalin with chemical sympathectomy, adrenal demedullation, hypophysectomy, or evisceration (Barron, B., and G. R. Van Loon, unpublished results). A small amount of circulating Met-enkephalin may derive from median eminence since levels are higher in hypothalamohypophyseal portal blood than in peripheral blood (Van Loon, G. R., and P. Plotsky, unpublished results).
Peptidase-derivable Met-enkephalin showed multiphasic response patterns to restraint stress which paralleled those for native Met-enkephalin, although the concentration varied from 150-to 375-fold higher than for native Met-enkephalin. The origin of the stress-induced increase in plasma peptidasederivable Met-enkephalin is more difficult to understand than is the origin of the stress-induced increase in native Met-enkephalin.
Repeated exposure to an identical stressor results in adaptive loss of the plasma catecholamine responses to stress ( 18). Thus, it was of considerable interest to determine whether the plasma Met-enkephalin responses to repeated exposure to stress showed a similar adaptation. Sympathoadrenal release of Met-enkephalin showed rapid adaptation of response; after 6 d of daily 30-min restraint stress, there were no longer plasma native or peptidase-derivable Met-enkephalin responses to restraint. Although the plasma epinephrine and norepinephrine responses to restraint were blunted after 6 d of daily 30-min restraint stress, they remained significant. This suggests to us that adaptation of the sympathetic nerve responses to a psychological stress occurs more readily than adaptation of the adrenomedullary responses. A somewhat different pattern of adaptation of plasma Met-enkephalin responses was seen with immobilization stress, and both native and peptidase-derivable Met-enkephalin showed cross-tolerance to hemorrhagic or electric footshock stress when adapted to immobilization (42) . It remains unknown whether adaptation of plasma Met-enkephalin responses to restraint or immobilization stress is mediated in brain, in the peripheral sympathoadrenal Met-enkephalin pool, or in both. A number of response patterns have been noted during adaptation of sympathoadrenal responses to chronic stress (46) . These include increased biosynthetic and storage capacity, elevated basal activity, attenuated responsiveness to homotypic stimulation and similar or potentiated responsiveness to novel stimulation. However, no clear hypothesis has emerged to unify these observations into a clear explanation ofadaptation ofthe sympathoadrenal responses to repeated stress.
The function of circulating Met-enkephalin remains elusive, but roles for opioid peptides in neuroendocrine (2) and cardiovascular regulation (37, 47, 48) as well as modulation of immune function (49) have been proposed. Although the plasma concentrations of native Met-enkephalin (5-50 pM) appear rather low to effectively mediate humoral responses, nanomolar to micromolar concentrations of peptidase-derivable Met-enkephalin demonstrated in plasma, and changes in plasma concentration of this peptidase-derivable Met-enkephalin in response to physiologic stimuli, suggest a functional role.
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